Cite
HARVARD Citation
Moran, T. et al. (2017). A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Lung cancer. pp. 154-160. [Online].